title: GFR decline as an end point in trials of CKD: a viewpoint from the FDA.
authors.affiliation: Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland. Electronic address: Aliza.Thompson@fda.hhs.gov.
authors.forename: Aliza
authors.initials: A
authors.lastname: Thompson
authors.affiliation: Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland.
authors.forename: John
authors.initials: J
authors.lastname: Lawrence
authors.affiliation: Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland.
authors.forename: Norman
authors.initials: N
authors.lastname: Stockbridge
mesh_terms: D004493:Education / Q000592:standards*; D023381:Endpoint Determination / Q000592:standards*; D005582:Foundations / Q000592:standards*; D005919:Glomerular Filtration Rate / Q000502:physiology*; D006801:Humans; D051436:Renal Insufficiency, Chronic / Q000175:diagnosis*; D014486:United States Food and Drug Administration / Q000592:standards*